Top

European Archives of Oto-Rhino-Laryngology

Published in:

01-04-2019 | Cytostatic Therapy | Head & Neck

Tumor volume as a predictive parameter in the sequential therapy (induction chemotherapy) of head and neck squamous cell carcinomas

Authors: M. Bohlen, C. -J. Busch, S. Sehner, F. Forterre, J. Bier, C. Berliner, L. Bußmann, A. Münscher

Published in: European Archives of Oto-Rhino-Laryngology | Issue 4/2019

Abstract

Purpose

Tumor volume in locally advanced head and neck squamous cell carcinomas (LAHNSCC) treated by induction chemotherapy (ICT) and followed by radiochemotherapy (RCT) was measured. The presence of potential correlation of initial tumor volume and volume reduction after ICT and RCT with remission status, overall survival (OS) and disease-free survival (DFS) were investigated. Furthermore, reliability of approximation of the tumor volume relying on its diameter to manual three-dimensional measurement was assessed.

Methods

Data of patients with LAHNSCC treated by ICT consisting of docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by definite RCT were retrospectively analyzed. The tumor volume was calculated slice-by-slice in contrast-enhanced CT or MRI before and after ICT as well as after complete treatment. The volume was compared to radiologic remission status, correlated with OS and DFS, and to volume estimation using tumor diameter.

Result

65 patients were included. Primary tumor volume did not correlate with complete remission rate (CR) after ICT and RCT, OS or DFS. The change in tumor volume between baseline imaging and post-RCT had a significant impact on OS (p = 0.026) and DFS (p = 0.028). The agreement between tumor volume and radiologic remission was 72.14%.

Conclusion

The initial tumor volume had no influence on CR, OS or DFS. A severe response to ICT did not predict a powerful RCT outcome. The change in tumor volume post-RCT had an impact on OS and DFS. Tumor volume estimation using its diameter seems to be a reliable method.

Available only for authorised users

Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRefPubMed

Colevas AD, Yom SS, Pfister DG et al (2018) NCCN guidelines insights: head and neck cancers, version 1.2018. J Natl Compr Canc Netw 16(5):479–490CrossRefPubMed

Forastiere AA, Adelstein DJ, Manola J (2013) Induction chemotherapy meta-analysis in head and neck cancer: right answer, wrong question. J Clin Oncol 31(23):2844–2846CrossRefPubMed

Ghi MG, Paccagnella A, Ferrari D et al (2017) Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol 28(9):2206–2212PubMed

Lorch JH, Goloubeva O, Haddad RI et al (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12(2):153–159CrossRefPubMedPubMedCentral

van Herpen CM, Mauer ME, Mesia R et al (2010) Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). Br J Cancer 103(8):1173–1181CrossRefPubMedPubMedCentral

Kurek R, Kalogera-Fountzila A, Muskalla K et al (2003) Usefulness of tumor volumetry as a prognostic factor of survival in head and neck cancer. Strahlenther Onkol 179(5):292–297CrossRefPubMed

Knegjens JL, Hauptmann M, Pameijer FA et al (2011) Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer. Head Neck 33(3):375–382PubMed

Dejaco D, Steinbichler T, Schartinger VH et al (2018) Prognostic value of tumor volume in patients with head and neck squamous cell carcinoma treated with primary surgery. Head Neck 40(4):728–739CrossRefPubMed

10.

Kimura Y, Sumi M, Ichikawa Y, Kawai Y, Nakamura T (2005) Volumetric MR imaging of oral, maxillary sinus, oropharyngeal, and hypopharyngeal cancers: correlation between tumor volume and lymph node metastasis. AJNR 26(9):2384–2389PubMedPubMedCentral

11.

Rutkowski T, Wygoda A, Skladowski K et al (2013) Prognostic role of tumor volume for radiotherapy outcome in patient with T2 laryngeal cancer. Strahlenther Onkol 189(10):861–866CrossRefPubMed

12.

Lok BH, Setton J, Caria N et al (2012) Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes. Int J Radiat Oncol Biol Phys 82(5):1851–1857CrossRefPubMed

13.

Mayr NA, Taoka T, Yuh WT et al (2002) Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys 52(1):14–22CrossRefPubMed

14.

Sorensen AG, Patel S, Harmath C et al (2001) Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 19(2):551–557CrossRefPubMed

15.

Dejaco D, Url C, Schartinger VH et al (2015) Approximation of head and neck cancer volumes in contrast enhanced CT. Cancer Imaging 15:16CrossRefPubMedPubMedCentral

16.

Baghi M, Mack MG, Hambek M et al (2007) Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy. Head Neck 29(2):104–108CrossRefPubMed

17.

Strongin A, Yovino S, Taylor R et al (2012) Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys 82(5):1823–1830CrossRefPubMed

18.

Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26(312):638–648CrossRefPubMed

19.

Johnson CR, Thames HD, Huang DT, Schmidt-Ullrich RK (1995) The tumor volume and clonogen number relationship: tumor control predictions based upon tumor volume estimates derived from computed tomography. Int J Radiat Oncol Biol Phys 33(2):281–287CrossRefPubMed

20.

Posner MR, Glisson B, Frenette G et al (2001) Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 19(4):1096–1104CrossRefPubMed

21.

Dietz A, Rudat V, Dreyhaupt J et al (2009) Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). Eur Arch Otorhinolaryngol 266(8):1291–1300CrossRefPubMed

22.

Lefebvre JL, Pointreau Y, Rolland F et al (2013) Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol 31(7):853–859CrossRefPubMed

23.

Haddad R, O’Neill A, Rabinowits G et al (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14(3):257–264CrossRefPubMed

24.

Hitt R, Grau JJ, Lopez-Pousa A et al (2014) A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 25(1):216–225CrossRefPubMed

25.

Forastiere AA, Zhang Q, Weber RS et al (2013) Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31(7):845–852CrossRefPubMed

26.

Prochnow S, Wilczak W, Bosch V, Clauditz TS, Muenscher A (2018) ERCC1, XPF and XPA-locoregional differences and prognostic value of DNA repair protein expression in patients with head and neck squamous cell carcinoma. Clin Oral Investig 1:1

27.

Nienstedt JC, Grobe A, Clauditz T et al (2017) High-level betaIII-tubulin overexpression occurs in most head and neck cancers but is unrelated to clinical outcome. J Oral Pathol Med 46(10):986–990PubMed

28.

Nienstedt JC, Schroeder C, Clauditz T et al (2018) EZH2 overexpression in head and neck cancer is related to lymph node metastasis. J Oral Pathol Med 47(3):240–245CrossRefPubMed

Title: Tumor volume as a predictive parameter in the sequential therapy (induction chemotherapy) of head and neck squamous cell carcinomas
Authors: M. Bohlen
C. -J. Busch
S. Sehner
F. Forterre
J. Bier
C. Berliner
L. Bußmann
A. Münscher
Publication date: 01-04-2019
Publisher: Springer Berlin Heidelberg
Keyword: Cytostatic Therapy
Published in: European Archives of Oto-Rhino-Laryngology / Issue 4/2019
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-019-05323-w

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Tumor volume as a predictive parameter in the sequential therapy (induction chemotherapy) of head and neck squamous cell carcinomas

Abstract

Purpose

Methods

Result

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2019

Syndromes that predispose to epistaxis

Diagnosis and treatment choices of suspected benign paroxysmal positional vertigo: current approach of general practitioners, neurologists, and ENT physicians

Rising incidences of Warthin’s tumors may be linked to obesity: a single-institutional experience

Perimarginal lymph nodes: an undervalued entity in oral cancer

Interobserver agreement of skeletal muscle mass measurement on head and neck CT imaging at the level of the third cervical vertebra

Decreased Treg-derived miR-181a and miR-155 correlated with reduced number and function of Treg cells in allergic rhinitis children